{
    "nct_id": "NCT03630289",
    "official_title": "Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Glioblastoma Multiforme (GBM)",
    "inclusion_criteria": "* Subject is a male or female 18 years of age or older.\n* Subject is undergoing planned resection of known or suspected GBM.\n* Subject has a Karnofsky Performance Status (KPS) 70% or greater.\n* Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.\n* Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region.\n* Subject must be able to undergo MRI evaluation.\n* Subject meets the following laboratory criteria:\n\n  * White blood count ≥ 3,000/µL\n  * Absolute neutrophil count ≥ 1,500/µL\n  * Platelets ≥ 100,000/µL\n  * Hemoglobin > 10.0 g/dL (transfusion and/or ESA allowed)\n  * Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN\n  * Blood urea nitrogen (BUN) and creatinine < 1.5 x ULN\n* Females of reproductive potential must have a negative serum pregnancy test and be willing to use an acceptable method of birth control.\n* Males of reproductive potential must be willing to use an acceptable method of birth control to ensure effective contraception with partner.\n* Able to understand and willing to sign an institutional review board (IRB)-approved written informed consent document (legally authorized representative permitted).\n\nInclusion criteria considered during surgery:\n\n* Subject has a histologically confirmed (frozen section) diagnosis of WHO Grade IV glioblastoma multiforme (GBM).\n* TPFF and/or pericranial flap is technically feasible.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject, if female, is pregnant or is breast feeding.\n* Subject has initiated chemotherapy or radiation treatment for diagnosis of or GBM.\n* Subject intends to participate in another clinical trial.\n* Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.\n* Subject has an active infection requiring treatment.\n* Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.\n* Subject has a history of other malignancy, unless the patient has been disease-free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment.\n* Subject has a known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection.\n* Subject has a history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.",
    "miscellaneous_criteria": ""
}